ARF6 and breast carcinoma: We previously demonstrated that simvastatin, as well as silvestrol, and GGT-II silencing inhibit the invasion of breast cancer cells overexpressing the ARF6-based pathway, and also decrease the cell surface expression of PD-L1 in PDAC cells.